Clinical Trials Browser

Phase 2/3 × Substance-Related Disorders × Dosage Forms × Clear all

NCT04345718 2025-12-09

EXHITENTRE

Phase 2/3 Completed

Lymphoma, Follicular, Opioid-Related Disorders, Substance-Related Disorders